Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0003873 (rheumatoid arthritis)
 53,068 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

A comparative study of the cytostatic drugs prospidin and cyclophosphamide used in equal doses for rheumatoid arthritis (RA) is reported. Clinical and immunologic effects were determined, and the nature and incidence of side effects and complications were compared. Prospidin showed a more pronounced antirheumatic effect, making for a smaller daily requirement of nonsteroid anti-inflammatory agents or hormones in hormone-dependent cases. Unlike cyclophosphamide, prospidin was not associated with severe side effects and complications precluding further use of the drug. Both drugs demonstrated a regulatory effect on RA-associated immunologic disorders.
 ...
PMID:[A new basic drug prospidin in the treatment of rheumatoid arthritis. III. Comparative analysis of prospidin and cyclophosphamide]. 303 35

A therapeutic effect of prospidine, a Soviet antitumor drug, was studied on the basis of clinicoimmunological correlations in 74 patients with proved rheumatoid arthritis (RA) who were resistant to well known basic drugs. It was administered parenterally and intraarticularly according to the methods developed by the authors, and its effect on the indices of T- and B-immune response was studied. Prospidine was shown to possess a true and high (91.8%) antirheumatic activity producing an analgesic, antiexudative and antiproliferative effect; it was capable of lessening hormone dependence and causing remission bringing about no serious side-effects which could require discontinuation of therapy. At the same time the use of the drug resulted in an elevation of the level of T-suppressors, a decrease in the amount of B-cells, T-helpers, titers of the rheumatoid factor, antisynovial antibodies, cytopathic and lymphokine synthesizing activity. Its mechanism of action and indications for use were discussed. Prospidine was considered as a drug of choice in drug therapy of rheumatoid arthritis.
 ...
PMID:[The new basic agent prospidin in the therapy of rheumatoid arthritis. An evaluation of the clinical effectiveness and the mechanism of action of prospidin]. 354 50

A study was made of the effect of the drugs with an immunostimulant (T-activin, levamisole) and immunosuppressant (prospidin) activity on the synthesis of IgA, IgM and IgG in vitro in lymphoid cultures of 7 healthy donors, 16 patients with seropositive and 9 patients with seronegative rheumatoid arthritis (RA). It was shown that the model of the synthesis of immunoglobulins in vitro demonstrates the impairment of T-B-cell cooperation of lymphocytes in RA patients. It was establised that the effect of immunologically active drugs on the synthesis of immunoglobulins depends on the character of the drug immunotropic action and initial functional activity of the immunoregulatory T-lymphocytes. Like polyclonal mitogens, levamisole and, to a greater extent, T-activin stimulating the initially low activity of T helpers increase spontaneous synthesis of immunoglobulins in lymphoid cultures of patients with seronegative RA, whereas in seropositive RA, these drugs stimulating the initially low activity of T suppressors carrying Fc gamma-receptors inhibit this process. Prospidin inhibit the synthesis of immunoglobulins equally in both RA patterns. Indications and contraindications for administration of he immunologically active drugs on a clinical bases are discussed.
 ...
PMID:[Correction of immunoregulatory disorders in seronegative and seropositive rheumatoid arthritis]. 387 5

Twenty-seven patients with highly active, refractory rheumatoid arthritis (RA) were treated with the new anti-rheumatic drug prospidine, in view of selecting the optimum pulse regimen and comparing its short-term use with methotrexate (MTX). Prospidine was administered intravenously 500 mg every 3-5 days in the hospital and then monthly. Fifteen patients received MTX (30 mg/week intravenously in hospital and then monthly. Fifteen patients received MTX (30 mg/week intravenously in hospital and then orally 7.5-15 mg/week). The randomisation code was 2:1. We assessed 7 clinical and 4 lab data. The clinical improvement was noticed statistically after 2-4 weeks in 85% prospidine-patients and sustained up to 6 months in 73% (cp. 40% and 57% by the MTX). Only in the prospidine patients were a significant reduction of the mean daily prednisolone dose and the levels of rheumatoid factor and immune complexes observed. Prospidine and MTX had a similar incidence of side effects (39% and 43%), but all drop-outs in prospidine pulse were due to lack of response (26%) and to initial intolerance (4%). Drop-outs in MTX pulse were connected both with drug toxicity (14%) and with lack of response (7%). Alternate prospidine pulse, as highly anti-inflammatory, rapidly acting and well-tolerated regimen, may be used in treating severe forms of RA.
 ...
PMID:Prospidine versus methotrexate pulse in highly active rheumatoid arthritis: a controlled 6-month clinical trial. 818 45